RT Journal Article
SR Electronic
T1 Expression of CD133 in differentiated thyroid cancer of young patients
JF Journal of Clinical Pathology
JO J Clin Pathol
FD BMJ Publishing Group Ltd and Association of Clinical Pathologists
SP 434
OP 440
DO 10.1136/jclinpath-2014-202625
VO 68
IS 6
A1 Decaussin-Petrucci, Myriam
A1 Deladoëy, Johnny
A1 Hafdi-Nejjari, Zakia
A1 Sassolas, Geneviève
A1 Borson-Chazot, Françoise
A1 Abu-Khudir, Rasha
A1 Fusco, Alfredo
A1 Descotes, Francoise
A1 Cournoyer, Sonia
A1 Sartelet, Hervé
A1 ,
YR 2015
UL http://jcp.bmj.com/content/68/6/434.abstract
AB Aims CD133 expression in cancer is frequently associated with poor outcome. Thyroid carcinomas are rare in childhood and adolescence and are associated with a higher risk of recurrence and more metastases than the adult tumours. The aim of the study was to assess whether the expression of CD133 in thyroid carcinomas of children, adolescents and young adults was correlated with clinical prognostic factors. Methods Tissue microarrays were constructed with 235 tumours coming from 208 young adults with a median age of 28 years and 27 children with a median age of 13 years. An immunohistochemical study was performed with anti-CD133 antibody. CD133 expression was evaluated, using a semiquantitative score based on the percentage of positive cells. The mutation status of tumours was evaluated by reverse transcriptase PCR. Three cell lines were used to confirm CD133 expression by western blot. Results CD133 expression was found in 43% of adult and 37% of child tumours and was confirmed by western blot in cell lines. In young adults, the expression of CD133 was significantly more frequent in patients with tumours >3 cm (p=0.04) and in patients with lymph node metastases (p=0.02). The expression of CD133 was more frequent in patients in whom the tumour presented a BRAF  mutation (p=0.03). Conclusions CD133 expression is correlated with tumour size, lymph nodes metastases and BRAF mutations in young adults. The presence of these cancer stem cells could offer new therapeutic alternatives for aggressive thyroid cancers.